Description
OVERVIEWProduct overview
AOD-9604 corresponds to the 176-191 region of human growth hormone, the portion associated in early literature with fat metabolism rather than with the growth-promoting activity of the full protein.
Preclinical work examines lipolytic activity in adipocyte cultures and body composition endpoints in rodent models, largely without the insulin-related effects attributed to intact growth hormone.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDAOD-9604 Ireland — supplied to research laboratories
Research groups across Ireland buy AOD-9604 from Kensington Laboratories as a lyophilised AOD-9604 peptide, released only against a batch-matched certificate of analysis. Every vial of high purity AOD-9604 is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering AOD-9604 in Ireland receive material with documented purity and identity.
Laboratory AOD-9604 is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning AOD9604 research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for AOD-9604 peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
AOD-9604 is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg per vial
- Peptide class: Synthetic C-terminal fragment of human growth hormone
- Also known as: Human growth hormone fragment 176-191
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
AOD-9604 corresponds to the 176-191 region of human growth hormone, the portion associated in early literature with fat metabolism rather than with the growth-promoting activity of the full protein.
Preclinical work examines lipolytic activity in adipocyte cultures and body composition endpoints in rodent models, largely without the insulin-related effects attributed to intact growth hormone.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Lipolysis in isolated adipocyte preparations
- Adipose tissue mass endpoints in rodent models
- Beta-3 adrenergic receptor expression studies
- Cartilage and joint tissue models
Scientific context and proposed mechanisms
Reported activity is attributed to stimulation of lipolytic pathways in adipose tissue and inhibition of lipogenesis, with several groups describing involvement of beta-3 adrenergic receptor expression rather than growth hormone receptor binding.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-AOD9604-2405A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 14 May 2026
- Reported purity
- 99.13%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
